NASDAQ:QNRX Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis → President Kamala (From Stansberry Research) (Ad) Free QNRX Stock Alerts $0.69 -0.03 (-4.19%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.68▼$0.7450-Day Range$0.63▼$0.8052-Week Range$0.60▼$12.00Volume43,615 shsAverage Volume354,133 shsMarket Capitalization$2.73 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Quoin Pharmaceuticals alerts: Email Address Quoin Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside482.9% Upside$4.00 Price TargetShort InterestHealthy0.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.03Based on 4 Articles This WeekInsider TradingSelling Shares$217 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.79) to ($0.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.75 out of 5 stars 3.5 Analyst's Opinion Consensus RatingQuoin Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageQuoin Pharmaceuticals has received no research coverage in the past 90 days.Read more about Quoin Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.30% of the outstanding shares of Quoin Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverQuoin Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quoin Pharmaceuticals has recently increased by 325.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldQuoin Pharmaceuticals does not currently pay a dividend.Dividend GrowthQuoin Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QNRX. Previous Next 1.1 News and Social Media Coverage News SentimentQuoin Pharmaceuticals has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Quoin Pharmaceuticals this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Quoin Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $217.00 in company stock.Percentage Held by InsidersOnly 3.30% of the stock of Quoin Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 8.63% of the stock of Quoin Pharmaceuticals is held by institutions.Read more about Quoin Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Quoin Pharmaceuticals are expected to grow in the coming year, from ($2.79) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quoin Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quoin Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuoin Pharmaceuticals has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Quoin Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchPresident KamalaThe sneaky (yet 100% legal) way for Obama to return to power The ONLY way Democrats can keep the White House is to bring back Barack Obama. And there's a sneaky (yet 100% legal) way to achieve this. In fact, this disaster scenario is already underway. See what they're up to, and how you can get ready today.Here's the full video exposé. About Quoin Pharmaceuticals Stock (NASDAQ:QNRX)Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.Read More QNRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QNRX Stock News HeadlinesJune 12 at 8:00 AM | globenewswire.comQuoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), IrelandMay 22, 2024 | finance.yahoo.comQNRX: Protocol Modifications Potentially Accelerate, Expand QRX003 ApprovalsMay 9, 2024 | msn.comQuoin Pharmaceuticals Non-GAAP EPS of -$1.11 misses by $0.70May 9, 2024 | finance.yahoo.comQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.comQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comQuoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024March 16, 2024 | seekingalpha.comQuoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | markets.businessinsider.comMaxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To KnowMarch 15, 2024 | finance.yahoo.comQuoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finanznachrichten.deQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial ResultsMarch 14, 2024 | benzinga.comQuoin Pharmaceuticals: Q4 Earnings InsightsMarch 13, 2024 | globenewswire.comQuoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial ResultsMarch 7, 2024 | msn.comWhy Quoin Pharmaceuticals (QNRX) Shares Are NosedivingMarch 7, 2024 | globenewswire.comQuoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ETMarch 6, 2024 | finance.yahoo.comQNRX: Potential Pool of Study Participants Expands; Financial Position StrengthsMarch 5, 2024 | seekingalpha.comQTI, RNLX and MTC among pre-market losersMarch 5, 2024 | msn.comWhy Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today?March 5, 2024 | finance.yahoo.comQuoin Pharmaceuticals Announces Pricing of $6.5 Million Public OfferingMarch 4, 2024 | marketwatch.comQuoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 TrialMarch 4, 2024 | markets.businessinsider.comQuoin Pharma Says FDA Clears Recruitment Of Teen Subjects For Two Ongoing Clinical Trials For QRX003March 4, 2024 | msn.comWhy Quoin Pharmaceutical Stock Is SoaringDecember 15, 2023 | markets.businessinsider.comBuy Rating for Quoin Pharmaceuticals Amid Promising Netherton Syndrome Drug ProspectsDecember 13, 2023 | morningstar.comQuoin Pharmaceuticals Ltd ADRDecember 13, 2023 | finanznachrichten.deQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton SyndromeDecember 13, 2023 | markets.businessinsider.comFDA Clears Quoin Pharma's Protocol Amendments For QRX003 Trials In Netherton Syndrome TreatmentSee More Headlines Receive QNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/15/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:QNRX CUSIPN/A CIK1671502 Webquoinpharma.com Phone(703) 980-4182Fax972-9767-8750Employees4Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+482.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($7.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,690,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-107.57% Return on Assets-56.01% Debt Debt-to-Equity RatioN/A Current Ratio3.61 Quick Ratio3.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.74 per share Price / Book0.12Miscellaneous Outstanding Shares3,980,000Free Float3,849,000Market Cap$2.73 million OptionableNot Optionable Beta1.89 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Michael Myers Ph.D. (Age 62)Co-Founder, CEO & Chairman Comp: $661.8kMs. Denise Carter (Age 55)Co-Founder, COO & Director Comp: $537.8kMr. Gordon Bruce Dunn J.D. (Age 60)Chief Financial Officer Comp: $394.2kKey CompetitorsElevai LabsNASDAQ:ELABVaccinexNASDAQ:VCNXAvalo TherapeuticsNASDAQ:AVTXMIRA PharmaceuticalsNASDAQ:MIRAChemomab TherapeuticsNASDAQ:CMMBView All CompetitorsInsiders & InstitutionsDennis LangerSold 297 sharesTotal: $216.81 ($0.73/share)Virtu Financial LLCBought 30,749 shares on 5/20/2024Ownership: 0.773%View All Insider TransactionsView All Institutional Transactions QNRX Stock Analysis - Frequently Asked Questions Should I buy or sell Quoin Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quoin Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" QNRX shares. View QNRX analyst ratings or view top-rated stocks. What is Quoin Pharmaceuticals' stock price target for 2024? 1 equities research analysts have issued 1-year price targets for Quoin Pharmaceuticals' stock. Their QNRX share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 482.9% from the stock's current price. View analysts price targets for QNRX or view top-rated stocks among Wall Street analysts. How have QNRX shares performed in 2024? Quoin Pharmaceuticals' stock was trading at $4.91 at the beginning of 2024. Since then, QNRX stock has decreased by 86.0% and is now trading at $0.6862. View the best growth stocks for 2024 here. Are investors shorting Quoin Pharmaceuticals? Quoin Pharmaceuticals saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 11,900 shares, an increase of 325.0% from the May 15th total of 2,800 shares. Based on an average trading volume of 100,100 shares, the days-to-cover ratio is presently 0.1 days. View Quoin Pharmaceuticals' Short Interest. When is Quoin Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our QNRX earnings forecast. How were Quoin Pharmaceuticals' earnings last quarter? Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) posted its quarterly earnings results on Thursday, May, 9th. The company reported ($1.11) earnings per share for the quarter. When did Quoin Pharmaceuticals' stock split? Quoin Pharmaceuticals's stock reverse split on Monday, July 17th 2023. The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are Quoin Pharmaceuticals' major shareholders? Quoin Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.77%). View institutional ownership trends. How do I buy shares of Quoin Pharmaceuticals? Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QNRX) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
